Quantitative Xylazine Measurement in ED

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

15 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-04-01

Study Completion Date

2026-02-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Quantitative Xylazine Measurement Among Non-Fatal Opioid Overdose (OD) Patients in the Emergency Department (ED)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neurobiology of Opioid Dependence: 3 - 3

NCT00000194

Opioid-Related Disorders

WITHDRAWN PHASE2

Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED

NCT02643355

Substance Withdrawal Syndrome

COMPLETED NA

Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls

NCT06789705

Central Diabetes Insipidus

RECRUITING NA

Temporal Dynamics and Pharmacokinetics of Intranasally Administered Oxytocin

NCT03011970

Healthy

COMPLETED PHASE1

The Effects of Fentanyl Abuse on Executive Function and Related Brain Activity

NCT05469217

Fentanyl Dependence

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Xylazine, a veterinary medication and alpha-2 agonist drug with clinical effects including prolonged sedation and skin/soft tissue wounds, has been increasingly detected with fentanyl in the illicit opioid supply. Due to its rapid emergence, limited knowledge exists regarding xylazine's health effects. In this proposed research, Dr. Love will measure xylazine and its metabolites in blood and urine samples using laboratory and point-of-care assays. Working at two New York City emergency departments, Dr. Love will collect waste serum and urine from opioid overdose patients to measure xylazine and its metabolite concentrations. The researcher will also perform qualitative assessment of urine samples with xylazine test strips to characterize urine xylazine detection using a harm reduction tool.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Opioid Overdose Substance Use Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Suspected Opioid Overdose

Individuals presenting to the ED with a suspected Opioid Overdose with Xylazine exposure.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ED patient
* Opioid OD (both NPS and non-NPS)
* Availability of waste blood specimens for analysis
* Availability of waste urine specimens for analysis